FDA approves Novo Nordisk's diabetes drug Ozempic for chronic kidney disease, expanding its use
1. FDA approved Ozempic for chronic kidney disease, enhancing its treatment use. 2. Ozempic reduced severe kidney outcomes by 24% in trial participants. 3. Approval indicates GLP-1 drugs have broader health benefits, beyond diabetes management. 4. Around 37 million Americans have chronic kidney disease, a major health challenge. 5. Novo Nordisk faces competition but expands drug's market potential significantly.